Online citations, reference lists, and bibliographies.
← Back to Search

Individual Growth Curve Analysis Of APOE ε4–Associated Cognitive Decline In Alzheimer Disease

B. Hoyt, P. Massman, C. Schatschneider, N. Cooke, R. Doody
Published 2005 · Psychology

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Background The apolipoprotein E e4 ( APOE e4 ) allele is associated with an increased risk of developing Alzheimer disease (AD). However, findings regarding an association between the APOE e4 allele and the rate of decline in AD have been mixed. Objective To examine the relationship between the APOE e4 allele and the rate of cognitive and functional decline in AD using individual growth curve analyses. Design Longitudinal cohort study. Setting Alzheimer Disease Research Center at Baylor College of Medicine. Patients A total of 189 patients meeting NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association) criteria for probable AD at baseline who underwent annual follow-up evaluations for at least 2 years. Main Outcome Measures Individual growth curve parameters derived from baseline and follow-up performance on global and specific measures of cognitive and functional abilities. Results Patients with 2 APOE e4 alleles exhibited a slower rate of decline on measures of global cognitive functioning and functional abilities. No significant association was detected between the APOE e4 allele and the rate of decline on measures of specific cognitive functions. Conclusions Although the APOE e4 allele is associated with an increased risk of developing AD, it seems that having 2 APOE e4 alleles is associated with a slower clinical course. These findings are consistent with hypotheses that the biological processes contributing to the onset of AD are different from those involved in determining its clinical course.
This paper references
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
G. Mckhann (1984)
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
J. Hixson (1990)
10.1002/ANA.410300410
Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
R. Terry (1991)
10.1037//0022-006X.59.1.27
Analysis of change: modeling individual growth.
D. Francis (1991)
10.1212/WNL.42.3.631
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Paulina V. Arriagada (1992)
10.1212/WNL.43.12.2457
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
J. Morris (1993)
10.1002/ANA.410370509
Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease
G. Frisoni (1995)
10.1212/WNL.45.7.1323
Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease
E. Corder (1995)
10.1093/GERONA/51A.4.M179
Application of a growth curve approach to modeling the progression of Alzheimer's disease.
Y. Stern (1996)
Apolipoprotein E genotype and rate of decline in probabole Alzheimer's disease
G. Forno (1996)
10.1001/ARCHNEUR.1996.00550040085017
Apolipoprotein E Genotype and Rate of Decline in Probable Alzheimer's Disease
E. H. Corder (1996)
10.1212/WNL.46.3.661
Prediction of probable Alzheimer's disease in memory-impaired patients
M. Tierney (1996)
10.1212/WNL.47.2.317
Apolipoprotein E and cognitive decline in Alzheimer's disease
Brenda L. Plassman (1996)
10.1176/AJP.154.5.603
No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.
G. Murphy (1997)
10.1002/ANA.410410510
The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's disease
Y. Stern (1997)
10.1523/JNEUROSCI.17-02-00516.1997
Plastic Neuronal Remodeling Is Impaired in Patients with Alzheimer’s Disease Carrying Apolipoprotein ε4 Allele
T. Arendt (1997)
10.1212/WNL.51.1.149
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
S. Craft (1998)
10.1037//0882-7974.14.2.295
Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease.
M. Bondi (1999)
10.1007/978-1-4615-4165-3_3
Introduction to Individual Growth Curve Analysis
D. Francis (2000)
10.1016/S0002-9440(10)64847-X
Effect of Apolipoprotein E Allele ε4 on the Initial Phase of Amyloid β-Protein Accumulation in the Human Brain
M. Morishima-kawashima (2000)
10.1001/ARCHNEUR.60.2.161
Apolipoprotein E, Alzheimer disease, and African Americans.
R. Mayeux (2003)



This paper is referenced by
10.3233/JAD-210685
Cognitive Decline in Alzheimer's Disease Is Not Associated with APOE.
I. Katzourou (2021)
10.3233/JAD-201182
Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer's Disease.
D. Loeffler (2021)
10.1002/dad2.12244
Brain atrophy trajectories predict differential functional performance in Alzheimer's disease: Moderations with apolipoprotein E and sex
Shraddha Sapkota (2021)
10.3233/JAD-210434
Segmented Linear Mixed Model Analysis Reveals Association of the APOE ɛ4 Allele with Faster Rate of Alzheimer’s Disease Dementia Progression
X. Richard Chen (2021)
10.1186/s13195-020-00712-4
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review
Sheina Emrani (2020)
10.1109/TCBB.2018.2870363
Gene Expressions, Hippocampal Volume Loss, and MMSE Scores in Computation of Progression and Pharmacologic Therapy Effects for Alzheimer's Disease
A. Saribudak (2018)
10.1097/WAD.0000000000000426
Functional Decline and Body Composition Change in Older Adults With Alzheimer Disease: A Retrospective Cohort Study at a Japanese Memory Clinic.
S. Murata (2020)
10.1002/trc2.12007
Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease
Kazushi Suzuki (2020)
10.1097/MD.0000000000020240
The impact of tamsulosin on cognition in Alzheimer disease with benign prostate hyperplasia
J. Sohn (2020)
10.1016/j.neurobiolaging.2020.06.001
Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition
S. Burnham (2020)
10.1016/j.brainres.2019.146519
Components of the choline oxidation pathway modify the association between the apolipoprotein ε4 gene variant and cognitive decline in patients with dementia
A. Hildre (2020)
10.1177/1178646919885637
The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein ε4 Allele Variant in Patients With Dementia
Arne Olav Ervik (2019)
10.3233/JAD-170665
Alzheimer's Disease Progression: Factors Influencing Cognitive Decline.
C. Ferrari (2017)
10.3233/JAD-180476
Risk Factors of Rapid Cognitive Decline in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.
Ya-nan Song (2018)
10.1016/j.jalz.2017.01.007
Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease
Jianping Jia (2017)
10.1145/2975167.2991037
Gene Expression Based Computation Methods for Alzheimer's Disease Progression using Hippocampal Volume Loss and MMSE Scores
A. Saribudak (2016)
10.1109/BIBE.2016.49
Computation of Pharmacologic Therapy Effects on Cognitive Abilities of Alzheimer’s Disease Patients
A. Saribudak (2016)
10.1371/journal.pone.0157514
The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease
Luise Christine Löwe (2016)
10.1016/j.jalz.2015.08.001
Trajectories of decline in cognition and daily functioning in preclinical dementia
V. Verlinden (2016)
10.1002/ana.24369
APOEε2 is associated with milder clinical and pathological Alzheimer disease
A. Serrano-Pozo (2015)
10.1016/j.euroneuro.2015.03.014
Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains
L. Smits (2015)
10.1016/j.chb.2014.11.044
Remote patient monitoring acceptance trends among older adults residing in a frontier state
J. Giger (2015)
10.1007/s12603-014-0028-0
Hierarchical structure of the activities of daily living scale in dementia.
F. Delva (2014)
Markers of Prognosis in Neurodegenerative Dementia
Kajsa Stubendorff (2014)
10.3233/JAD-130623
Cognitive impairment in neurological diseases: lessons from apolipoprotein E.
J. Shi (2013)
10.3233/JAD-131862
Natural history of functional decline in Alzheimer's disease: a systematic review.
F. Delva (2014)
Pronostic de la démence
Mathilde Fleur Grégoire-Delva (2014)
10.1016/j.jalz.2013.05.1763
APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease
Yu-Ling Chang (2014)
10.3109/09540261.2013.859128
Rapid cognitive decline in Alzheimer's disease: a literature review
Alessandro Sona (2013)
10.1093/brain/awt127
Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
J. Foster (2013)
10.1016/j.jagp.2012.10.005
Caregiver coping strategies predict cognitive and functional decline in dementia: the Cache County Dementia Progression Study.
J. Tschanz (2012)
10.1186/alzrt210
Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies
C. Wattmo (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar